SAN JOSE, Calif., May 27, 2025 /PRNewswire/ — Resurge Therapeutics, a privately held therapeutics company, announced promising six-month clinical results from the initial dose cohort of the ongoing first-in-human study evaluating its novel IntraProstatic Drug Elution (IPDE) therapy. The…
